NATH BIOGENES (INDIA)
|
NATH BIOGENES (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2013 | Mar2012 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 18.43 | -35.46 | 7.34 | 5.75 |
| CEPS(Rs) | 20.01 | -33.84 | 10.16 | 8.69 |
| DPS(Rs) | 2.00 | 2.00 | - | - |
| Book NAV/Share(Rs) | 301.61 | 285.16 | 35.91 | 28.57 |
| Tax Rate(%) | 3.19 | -6.23 | 4.48 | -1.38 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 16.21 | 13.37 | 14.45 | 11.84 |
| EBIT Margin(%) | 15.39 | -18.96 | 11.60 | 8.78 |
| Pre Tax Margin(%) | 12.00 | -22.79 | 8.93 | 7.32 |
| PAT Margin (%) | 11.62 | -24.21 | 8.53 | 7.42 |
| Cash Profit Margin (%) | 12.62 | -23.10 | 11.80 | 11.22 |
| Performance Ratios | ||||
| ROA(%) | 4.57 | -15.03 | 8.50 | 7.73 |
| ROE(%) | 6.28 | -22.48 | 22.76 | 20.12 |
| ROCE(%) | 7.06 | -14.84 | 23.88 | 19.09 |
| Asset Turnover(x) | 0.39 | 0.62 | 1.00 | 1.04 |
| Sales/Fixed Asset(x) | 1.12 | 1.62 | 2.08 | 2.22 |
| Working Capital/Sales(x) | 0.99 | 1.02 | 6.37 | 5.12 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.89 | 0.62 | 0.48 | 0.45 |
| Receivable days | 110.74 | 69.85 | 44.32 | 36.68 |
| Inventory Days | 259.30 | 195.06 | 189.43 | 193.69 |
| Payable days | 744.29 | 1,503.38 | -4,219.16 | 1,576.65 |
| Valuation Parameters | ||||
| PER(x) | 7.69 | - | - | - |
| PCE(x) | 7.08 | -6.31 | - | - |
| Price/Book(x) | 0.47 | 0.75 | - | - |
| Yield(%) | 1.41 | 0.94 | - | - |
| EV/Net Sales(x) | 1.12 | 1.78 | 0.24 | 0.19 |
| EV/Core EBITDA(x) | 6.81 | 12.65 | 1.60 | 1.54 |
| EV/EBIT(x) | 7.26 | -9.36 | 2.05 | 2.20 |
| EV/CE(x) | 0.42 | 0.67 | 0.21 | 0.20 |
| M Cap / Sales | 0.89 | 1.46 | - | - |
| Growth Ratio | ||||
| Net Sales Growth(%) | 8.26 | 102.15 | 11.13 | - |
| Core EBITDA Growth(%) | 26.40 | 90.81 | 31.43 | - |
| EBIT Growth(%) | 187.85 | -430.58 | 46.76 | - |
| PAT Growth(%) | 151.96 | -673.70 | 27.66 | - |
| EPS Growth(%) | 151.98 | -583.10 | 27.66 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.18 | 0.17 | 0.33 | 0.25 |
| Current Ratio(x) | 2.41 | 2.41 | 1.22 | 1.34 |
| Quick Ratio(x) | 1.45 | 1.27 | 0.43 | 0.42 |
| Interest Cover(x) | 4.54 | -4.96 | 4.35 | 6.02 |
| Total Debt/Mcap(x) | 0.39 | 0.23 | - | - |
Compare Financial Ratios of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹381.0 Cr | 0.8% | -15.2% | 27.9% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹11,022.2 Cr | 1.9% | -9.3% | 86.3% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,884.7 Cr | -1.5% | -5.4% | 22.2% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,477.9 Cr | -0.4% | -13.5% | -1.3% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹2,310.2 Cr | NA | -11.6% | -31.3% | Stock Analytics | |
| TIERRA AGROTECH | ₹449.7 Cr | 3.7% | -21.5% | -47.8% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 0.8% |
-15.2% |
27.9% |
| SENSEX | 0.5% |
1.4% |
23.5% |
You may also like the below Video Courses
